Cell therapy combo aims to boost kidney cancer treatment

NCT ID NCT07087158

Recruiting now Disease control Sponsor: Imbioray (Hangzhou) Biomedicine Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 02, 2026 · Last updated Jul 02, 2026

Summary

This study tests whether adding an experimental cell therapy called IBR854 to the standard drug pazopanib works better than pazopanib alone for advanced kidney cancer. About 30 adults with untreated advanced clear cell renal cell carcinoma will take part. The goal is to see if the combination slows cancer growth and improves survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IBR854 (a cell therapy) combined with pazopanib (a targeted drug)
What this could lead to: If successful, this combination could offer a new treatment option for people with advanced kidney cancer that hasn't been treated before.
What could go wrong: This is an early phase 2 trial with only 30 participants, so results may not apply broadly. Cell therapies can cause serious side effects like immune reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED CLEAR CELL RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

clear cell renal carcinoma renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RENAL CELL CARCINOMA (RCC)

Contacts and locations

Locations

The Cancer Hospital of Fudan University
RECRUITING

Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.